Literature DB >> 3392415

Serological evidence of possible human infection with Ehrlichia in Texas.

J P Taylor1, T G Betz, D B Fishbein, M A Roberts, J Dawson, M Ristic.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3392415     DOI: 10.1093/infdis/158.1.217

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  8 in total

1.  Canine ehrlichiosis in Connecticut.

Authors:  L A Magnarelli; H J Litwin; C J Holland; J F Anderson; M Ristic
Journal:  J Clin Microbiol       Date:  1990-02       Impact factor: 5.948

2.  Epidemiologic and clinical characteristics of persons with serologic evidence of E. canis infection.

Authors:  B W Rohrbach; J R Harkess; S A Ewing; J Kudlac; G L McKee; G R Istre
Journal:  Am J Public Health       Date:  1990-04       Impact factor: 9.308

3.  Ehrlichia chaffeensis expresses an immunoreactive protein homologous to the Escherichia coli GroEL protein.

Authors:  J W Sumner; K G Sims; D C Jones; B E Anderson
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

Review 4.  The tribe Ehrlichieae and ehrlichial diseases.

Authors:  Y Rikihisa
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

Review 5.  Epidemiology of rickettsial diseases.

Authors:  D H Walker; D B Fishbein
Journal:  Eur J Epidemiol       Date:  1991-05       Impact factor: 8.082

6.  Rickettsiae and Borrelia burgdorferi in ixodid ticks.

Authors:  L A Magnarelli; T G Andreadis; K C Stafford; C J Holland
Journal:  J Clin Microbiol       Date:  1991-12       Impact factor: 5.948

7.  In vitro antibiotic susceptibility of the newly recognized agent of ehrlichiosis in humans, Ehrlichia chaffeensis.

Authors:  P Brouqui; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

Review 8.  Ehrlichia chaffeensis: a prototypical emerging pathogen.

Authors:  Christopher D Paddock; James E Childs
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.